Investors Research Corp Has $1.07 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Investors Research Corp decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 16.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,536 shares of the biopharmaceutical company’s stock after selling 2,216 shares during the quarter. Investors Research Corp’s holdings in Gilead Sciences were worth $1,066,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in GILD. HHM Wealth Advisors LLC boosted its stake in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares in the last quarter. YANKCOM Partnership acquired a new position in shares of Gilead Sciences during the fourth quarter worth $28,000. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences in the 4th quarter valued at $29,000. Crews Bank & Trust acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at $31,000. Finally, Stephens Consulting LLC grew its position in Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 260 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

GILD stock opened at $117.41 on Monday. The firm has a 50 day simple moving average of $99.61 and a two-hundred day simple moving average of $91.62. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $118.42. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a market cap of $146.22 billion, a PE ratio of 317.32, a P/E/G ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s payout ratio is presently 854.05%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research note on Thursday, February 13th. Wells Fargo & Company boosted their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Mizuho increased their price target on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, November 21st. Finally, UBS Group boosted their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $104.24.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 8,500 shares of Gilead Sciences stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $91.96, for a total transaction of $781,660.00. Following the completion of the transaction, the chief financial officer now directly owns 132,373 shares of the company’s stock, valued at $12,173,021.08. This trade represents a 6.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold 293,356 shares of company stock worth $29,166,240 over the last 90 days. 0.16% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.